GCKR and Hypoglycemia: The glucose‐lowering effects induced by these GCKR small‐molecule disruptors was restricted to diabetic and non‐normoglycaemic animals, suggesting an advantage in preventing adverse effects of drug treatment, which may lead to hypoglycemia.